A Prospective, Randomized Controlled Trial to Assess the Impact of MyTatva Application in Management of Nonalcoholic Fatty Liver Disease - RESET

Digicare Health Solutions Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•Patients with confirmed diagnosis of NAFLD
•Patients with Liver Stiffness Measure (LSM) Values ranges between 7 to 12 kPa measured via FibroScan
•Patients with access to a smartphone with internet access/data plan
•Patients or caregivers who understands and speaks English sufficiently to be able to use the MyTatva Patient application
•Patient is willing to comply with all study procedures and available for the duration of study

•Patients who have active or recent participation in lifestyle intervention program including a weight loss program less than 90 days before enrolment
•Patients who are on active weight loss supplement use
•Patients with LSM values above 12 kPa measured via FibroScan
•Patients who are unable or not willing to provide informed consent
•Patients with other chronic liver diseases
•Patients who have secondary causes of hepatic steatosis,
•including significant alcohol consumption for men more than 30gram per day and women more than 20gram day
•Patients who have severe medical comorbidities or psychiatric illness can be excluded at the discretion of the study PI
•Concurrent enrollment in any other interventional clinical trial at the start of study
•Enrollment in any other interventional clinical trial 3 months prior to the start of study
•Presumed or confirmed COVID-19 diagnosis within 30 days prior to study enrollment

发起方

Digicare Health Solutions Private Limited